Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.
(Bloomberg) -- Novavax Inc. shares had their biggest loss in more than three years as the drugmaker slashed its 2022 revenue forecast late Monday on disappointing demand for its Covid-19 vaccine that trailed competitors getting to market.Most Read from BloombergTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoChina Seizes on Pelosi Visit to Set ‘New Normal’ for TaiwanSan Francisco ‘Froth is Gone’ as Wealth Fades, Housing SlumpsWhy Carlyle's Billionaire Founders Had Enough of Their
The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday. The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe. A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.